AbbVie

Open: 141.89 Close: 141.2 Change: -0.69

You don't have time to read all about AbbVie. An AI summarizes all the information for you.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Investors in AbbVie (NYSE:ABBV) have seen solid returns of 101% over the past five years. Investors in ABbVies earnings per share are down 5.3% per year, despite strong share price.

Today's News

Investors in AbbVie (NYSE:ABBV) have seen solid returns of 101% over the past five years. Investors in ABbVies earnings per share are down 5.3% per year, despite strong share price. AbbVie Inc. per Employee $1.103M P/E Ratio 38.58 - $3.66 Yield 4.39% Dividend $1.55 Ex-Dividend Date Jan 12, 2024 Short Interest 11.47M 10/13/23. AbbVie declares $1.48 dividend. Allergan Aesthetics celebrating the fifth annual BOTOX® Cosmetic Day on November 15. The role will report directly to the Office of Ethics & Compliance (OEC) Director of Global Risk, Analytics and Operational Excellence. The position will support the development of the strategy, tactics, and supporting ongoing execution execution execution. AbbVie Bet To Swap Parkinsons Patent Claims Fails At PTAB. Patent Trial and Appeal Board has canceled every claim in an Abbvie Inc. stock. ABBVie is the 35th most valuable company by market cap. Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie for license to develop, manufacture and commercialize reproxalap, Aldeyras candidate in development for d... Amgen (AMGN.O) on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition of Horizon Therapeutics. Sales of Amjevita, Amgens new biosimilar version of AbbVies (ABBVies). AbbVie Inc. partner Ironwood and Abbvie share equally in U.S. net sales. AbbVie will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie stock has received a consensus rating of buy. The 48 analysts offering price forecasts for Abbvie stock have a median target of 166.50, with a high estimate of 200.00 and a low estimate of 113.00. The high in the last 52 weeks of Abb vie stock was 168.09.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, stock, share, Inc, execution, Abbvie, sale, and the most common words in the summary are: abbvie, stock, market, inc, news, buy, option, . One of the sentences in the summary was: Investors in ABbVies earnings per share are down 5.3% per year, despite strong share price.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #inc #news #buy #option.